Quick Answer
Century Therapeutics, Inc. reported Diluted EPS of $0.14 per share (loss) for fiscal year 2025.
Century Therapeutics, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$0.14 | +91.3% |
| 2024 | -$1.61 | +30.0% |
| 2023 | -$2.30 | +22.3% |
| 2022 | -$2.96 | +0.0% |
| 2021 | -$2.96 | +58.7% |
| 2020 | -$7.16 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.40 | -8.1% | -5.3% |
| June 30, 2025 | -$0.38 | +0.0% | -142.7% |
| March 31, 2025 | $0.89 | +297.8% | +340.5% |
| September 30, 2024 | -$0.37 | +32.7% | +2.6% |
| June 30, 2024 | -$0.38 | +32.1% | +15.6% |
| March 31, 2024 | -$0.45 | +15.1% | +18.2% |
| September 30, 2023 | -$0.55 | -3.8% | +1.8% |
| June 30, 2023 | -$0.56 | -3.7% | -5.7% |
- Century Therapeutics, Inc. showed an increase of +91.3% in Diluted EPS compared to the prior fiscal year.
- Over the 2020–2025 period, Century Therapeutics, Inc.’s diluted eps has grown by 98.0% (from $7.16 per share (loss) to $0.14 per share (loss)).
- The most recent figure is from Century Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: